Patent ID: 6599899
Filing Date: 2003-07-29
Classification: A61P,C07D

Abstract:
A method of treating a subject suffering from a disorder in glucose and lipid metabolism, which comprises administering to the subject a therapeutically effective amount of the compound of the Formula (I), or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug form, or a pharmaceutically acceptable salt thereof, whereinQ is a fused phenyl or fused pyridyl moiety; Z1 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, phenyl, hydroxy, amino, nitro, sulfonylamino or trifluoromethyl; Z2 is hydrogen or halogen; X is hydrogen or oxygen; n is an integer from 0-3; and Y is selected from (a) N+HR1R2, N+R1R2R3; (b) NHC(&boxH;NR4)NHR5; (c) CO2H, CHO; (d) CH(R6)COOH, CH(R6)COOCH3, CH&boxH;CHR7, CH&boxH;C(COOH)2; (e) a moiety of the formula (f) 5-tetrazolyl, whereinR1, R2 and R3 are independently hydrogen, C1-C6 alkyl, or t-butoxycarbonyl; R4 and R5 are independently t-butoxycarbonyl or hydrogen, or R4 and R5 may be joined together to form an imidazoline, imidazolyl or pyrimidine ring; R6 is hydrogen, hydroxy, or halogen; and R7 is CO2H or C(O)NH(CH2)pOH wherein p is an integer from 1-4.